CLNNClene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, w…
Industry Peers
Packaged Foods| Headline | Source | Time |
|---|---|---|
Older | ||
 Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses Clene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an intervie | ||
 Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates Clene (CLNN) delivered earnings and revenue surprises of -62.16% and +38.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS Clene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration. President and CEO Rob Etherington said the co | ||
 Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates Microbot Medical (MBOT) delivered earnings and revenue surprises of 0.00% and -22.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||